RU2004115337A - Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибмтора сох-2 и таксола - Google Patents
Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибмтора сох-2 и таксола Download PDFInfo
- Publication number
- RU2004115337A RU2004115337A RU2004115337/15A RU2004115337A RU2004115337A RU 2004115337 A RU2004115337 A RU 2004115337A RU 2004115337/15 A RU2004115337/15 A RU 2004115337/15A RU 2004115337 A RU2004115337 A RU 2004115337A RU 2004115337 A RU2004115337 A RU 2004115337A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- cox
- bisphosphonate
- effective amount
- taxol
- Prior art date
Links
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract 7
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract 6
- 229960001592 paclitaxel Drugs 0.000 title claims abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 4
- 239000003112 inhibitor Substances 0.000 title claims 3
- 230000003211 malignant effect Effects 0.000 title abstract 3
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 title 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract 10
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract 9
- 238000000034 method Methods 0.000 claims abstract 9
- 229940111134 coxibs Drugs 0.000 claims abstract 8
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229930184616 taxin Natural products 0.000 claims 1
- KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (11)
1. Фармацевтическая композиция для лечения злокачественных опухолей, которая включает в комбинации бифосфонат и ингибитор СОХ-2, для одновременного, последовательного или раздельного применения.
2. Применение ингибитора СОХ-2 при получении лекарственного средства для применения в комбинации с бифосфонатом в лечении заболевания злокачественной опухолью.
3. Способ лечения пациента, страдающего заболеванием злокачественной опухолью, включающий введение пациенту эффективного количества бифосфоната и эффективного количества ингибитора СОХ-2.
4. Фармацевтическая композиция по п.1, применение по п.2 или способ по п.3 для подавления роста раковой клетки или индукции апоптоза раковой клетки.
5. Способ лечения пациента, страдающего заболеванием злокачественной опухолью, включающий введение пациенту эффективного количества бифосфоната, эффективного количества ингибитора СОХ-2 и эффективного количества таксола или его производного.
6. Способ по п.3 или 5, в котором бифосфонат означает N-бифосфонат.
7. Способ по п.6, в котором бифосфонат означает соединение формулы I
где Х означает водород, гидроксил, амино, алканоил или аминогруппу, замещенную (С1-С4)алкилом или алканоилом;
R означает водород или (С1-С4)алкил, и
Rx означает боковую цепь, которая содержит необязательно замещенную аминогруппу, или азотсодержащий гетероцикл (включая ароматические азотсодержащие гетероциклы), или его фармацевтически приемлемую соль или любой его гидрат.
8. Способ по п.7, в котором бифосфонат означает 2-(имидазол-1-ил)-1-гидроксиэтан-1,1-дифосфоновую кислоту (золедроновую кислоту) или ее фармацевтически приемлемую соль.
9. Способ по п.3, в котором ингибитор СОХ-2 означает ингибитор, который имеет значение IC50 для ингибирования СОХ-2 меньше, чем примерно 2 мкМ, и значение IC50 для ингибирования СОХ-1 больше, чем примерно 5 мкМ.
10. Способ по п.9, в котором ингибитор СОХ-2 выбирают из группы, состоящей из рофекоксиба, эторикоксиба, целекоксиба, вальдекоксиба, парекоксиба или ингибитора СОХ-2 на основе производного 5-алкил-2-ариламинофенилуксусной кислоты или ее фармацевтически приемлемой соли, или любого ее гидрата.
11. Композиция по п.1, включающая эффективное количество таксола, паклитаксела, таксотера, доцетаксела, таксана, таксина или любого другого подходящего производного таксола.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34592101P | 2001-10-19 | 2001-10-19 | |
| US60/345,921 | 2001-10-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2004115337A true RU2004115337A (ru) | 2005-04-20 |
| RU2317819C2 RU2317819C2 (ru) | 2008-02-27 |
Family
ID=23357099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004115337/15A RU2317819C2 (ru) | 2001-10-19 | 2002-10-18 | Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибитора сох-2 и таксола |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7345088B2 (ru) |
| EP (1) | EP1443942B1 (ru) |
| JP (1) | JP2005506371A (ru) |
| KR (1) | KR20040066103A (ru) |
| CN (1) | CN100372539C (ru) |
| AT (1) | ATE382347T1 (ru) |
| AU (1) | AU2002363089B2 (ru) |
| BR (1) | BR0213410A (ru) |
| CA (1) | CA2461085A1 (ru) |
| CO (1) | CO5570672A2 (ru) |
| DE (1) | DE60224429T2 (ru) |
| DK (1) | DK1443942T3 (ru) |
| EC (1) | ECSP045054A (ru) |
| ES (1) | ES2301710T3 (ru) |
| HU (1) | HUP0402061A3 (ru) |
| IL (2) | IL161090A0 (ru) |
| MX (1) | MXPA04003671A (ru) |
| NO (1) | NO20042056L (ru) |
| NZ (1) | NZ532282A (ru) |
| PL (1) | PL367707A1 (ru) |
| PT (1) | PT1443942E (ru) |
| RU (1) | RU2317819C2 (ru) |
| SI (1) | SI1443942T1 (ru) |
| WO (1) | WO2003035081A1 (ru) |
| ZA (1) | ZA200402089B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204756D0 (en) * | 2002-02-28 | 2002-04-17 | Novartis Ag | Organic compounds |
| GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| KR101813728B1 (ko) | 2009-07-31 | 2017-12-29 | 그뤼넨탈 게엠베하 | 결정화 방법 및 생체이용률 |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187130A (zh) * | 1995-06-06 | 1998-07-08 | 麦克公司 | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 |
| JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| WO2001054688A1 (en) * | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
-
2002
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en not_active Ceased
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Ceased
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
-
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0402061A3 (en) | 2007-05-29 |
| US7345088B2 (en) | 2008-03-18 |
| US20050014726A1 (en) | 2005-01-20 |
| PT1443942E (pt) | 2008-04-07 |
| DK1443942T3 (da) | 2008-05-19 |
| EP1443942B1 (en) | 2008-01-02 |
| ES2301710T3 (es) | 2008-07-01 |
| DE60224429D1 (de) | 2008-02-14 |
| KR20040066103A (ko) | 2004-07-23 |
| CO5570672A2 (es) | 2005-10-31 |
| DE60224429T2 (de) | 2008-12-18 |
| AU2002363089B2 (en) | 2006-02-16 |
| JP2005506371A (ja) | 2005-03-03 |
| ECSP045054A (es) | 2004-05-28 |
| EP1443942A1 (en) | 2004-08-11 |
| SI1443942T1 (sl) | 2008-08-31 |
| NZ532282A (en) | 2006-02-24 |
| CN1703226A (zh) | 2005-11-30 |
| PL367707A1 (en) | 2005-03-07 |
| HK1080733A1 (en) | 2006-05-04 |
| HUP0402061A2 (hu) | 2005-02-28 |
| IL161090A (en) | 2010-04-15 |
| MXPA04003671A (es) | 2005-06-20 |
| IL161090A0 (en) | 2004-08-31 |
| WO2003035081A1 (en) | 2003-05-01 |
| RU2317819C2 (ru) | 2008-02-27 |
| BR0213410A (pt) | 2004-11-03 |
| ATE382347T1 (de) | 2008-01-15 |
| ZA200402089B (en) | 2005-06-22 |
| CN100372539C (zh) | 2008-03-05 |
| NO20042056L (no) | 2004-05-18 |
| CA2461085A1 (en) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2365372C2 (ru) | Циклические ингибиторы протеинтирозинкиназ | |
| BRPI0413255A (pt) | uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer | |
| BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
| WO2004043374A3 (en) | Methods and compositions for treating cancer using proteasome inhibitors | |
| RU2004115337A (ru) | Фармацевтическая композиция для применения в терапии злокачественных новообразований, включающая комбинацию бифосфоната, ингибмтора сох-2 и таксола | |
| Gander et al. | Malignancy mimicking bisphosphonate-associated osteonecrosis of the jaw: a case series and literature review | |
| JP2004530655A5 (ru) | ||
| BRPI0414736A (pt) | 5-aril-pirimidinas como agentes anticáncer | |
| ATE345790T1 (de) | Kombination von einem aromatasehemmer mit einem bisphosphonat | |
| Salesi et al. | Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases | |
| RU2006123939A (ru) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы | |
| BR0213486A (pt) | Combinações que compreendem um inibidor seletivo de ciclooxigenase-2 | |
| CA2596084A1 (en) | Treatment of metastasized tumors with quinolinone benzimidazole compounds | |
| Shoji et al. | Intravascular administration of acridine orange and zoledronate in a bone metastasis model of breast cancer | |
| ATE386029T1 (de) | Urokinase-inhibitoren | |
| US20070219115A1 (en) | Pharmaceutical Uses of Bisphosphonates | |
| JP2007513118A5 (ru) | ||
| TH70460A (th) | สิ่งที่รวมกันของตัวที่ขัดขวางคะเทพซินเค (Cathepsin K) และบีสฟอสโฟเนท ในการทำการบำบัดมีแทสทาซีสของกระดูกการเติบโตของเนื้องอก และการเสียกระดูกที่ถูกชักนำโดยเนื้องอก | |
| Zakhary et al. | Idiopathic incidence of MRONJ in patients on denosumab | |
| UA63666A (en) | Method for treating primary squamous cell cancer of anal region | |
| Choi et al. | Treatment of bone metastasis in breast cancer | |
| MXPA06006278A (en) | Pharmaceutical uses of bisphosphonates | |
| BR0302183A (pt) | Composto, composição farmacêutica e uso de um composto | |
| Rajbhandari et al. | 1133: Cell Adhesion Molecule L1 Counteracts Oxidative Stress-Induced Cell Death: A Potential Radiotherapy Target for Prostate Cancer Bone Metastasis | |
| WO2003090737A3 (en) | Methods and compositions for treatment of cancer pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20091019 |